Login
Vericel NASDAQ: VCEL
Vericel Corporation, formerly Aastrom Biosciences, Inc. is a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions - dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues
| Name | Vericel |
| Ticker | VCEL |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Price | 41.23 |
| 52W Low/High | 7.25 / 41.23 |
| Market cap | 1.9 B |
| 1Y Total Return |
145.12%
Strong |
| 1Y Volatility |
69.21%
More Risk |
Vericel Corporation, formerly Aastrom Biosciences, Inc. is a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions - dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues
Details
| Ticker | VCEL |
| Name | Vericel |
| ISIN | US92346J1088 |
| CUSIP | 92346J108 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 1/22/21
| Close Price | 41.23 |
| 52W Low/High | 7.25 / 41.23 |
| Market cap | 1.9 B |
| 1Y Total Return |
145.12%
Strong |
| 1Y Volatility |
69.21%
More Risk |
| Beta | 1.30 |
| PE (trailing) |
2,061.50
High |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | 0.1% |
| Cash from Op. / Cur. Liabilities | 0.44 |
| Diluted Earnings / Share | 0.02 |
| ROE | 0.1% |
| ROIC | 0.2% |
| Price / Revenue | 16.5 |
| Price / Book | 17.0 |
| Price / CF | 207.9 |
| Current Ratio | 5.9 |
| Cur.Liabilities / Tot.Liabilities | 0.5 |
| Financial Leverage | 0.24 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
118
|
110
|
83
|
57
|
53
|
50
|
|
| Gross Profit |
79
|
74
|
51
|
28
|
25
|
24
|
|
| R&D |
13
|
30
|
14
|
14
|
18
|
17
|
|
| EBITDA |
6
|
-10
|
-10
|
-21
|
-16
|
-12
|
|
| Operating Income |
-1
|
-14
|
-9
|
-22
|
-18
|
-14
|
|
| Net Income exc. Extra |
0
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
47
|
47
|
43
|
34
|
23
|
24
|
|
| EPS exc. Extra |
0.02
|
-0.31
|
-0.33
|
-0.88
|
-1.12
|
-0.02
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
158
|
138
|
124
|
40
|
28
|
36
|
|
| Cash, Eq & Invt ShortTerm |
86
|
75
|
98
|
15
|
9
|
19
|
|
| Total Current Assets |
125
|
105
|
119
|
36
|
21
|
29
|
|
| Total Non-Current Assets |
32
|
33
|
5
|
4
|
7
|
7
|
|
| Intangibles |
0
|
0
|
0
|
0
|
3
|
3
|
|
| Total Liabilities |
43
|
41
|
30
|
24
|
17
|
9
|
|
| Total Current Liabilities |
21
|
15
|
15
|
15
|
15
|
9
|
|
| Long Term Debt |
22
|
25
|
15
|
9
|
1
|
0
|
|
| Shareholder equity |
115
|
97
|
94
|
17
|
11
|
26
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
9
|
-8
|
-2
|
-23
|
-15
|
-16
|
|
| Depreciation |
6
|
3
|
2
|
2
|
2
|
1
|
|
| Cash from Investing |
-6
|
5
|
-47
|
-1
|
-1
|
-3
|
|
| Capex |
2
|
3
|
3
|
1
|
1
|
3
|
|
| Cash from Financing |
4
|
-13
|
87
|
31
|
6
|
0
|
|
| Stock Issued |
4
|
5
|
81
|
27
|
0
|
0
|
|
| Debt (LT) Issued |
0
|
-18
|
7
|
4
|
6
|
0
|
|
| Free Cash Flow |
-1
|
-26
|
-17
|
-33
|
-13
|
-30
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
0.1%
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
5.9
|
6.9
|
8.0
|
2.5
|
1.4
|
3.1
|
|
| Financial Leverage D/E |
0.24
|
0.29
|
0.18
|
0.59
|
0.49
|
0.00
|
|
| Return on Capital Avg |
0.2%
|
-19.1%
|
-34.7%
|
-322.3%
|
-313.1%
|
-338.3%
|
|
| Return on Shareholder Equity |
0.1%
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available